Pharmicell Co: H1 2024 saw lower sales and profit, but Bio-Chemical remains the main growth engine

About this update from Pharmicell Co., Ltd

Revenue and profit declined sharply in H1 2024, with Bio-Chemical driving nearly all sales and profit. R&D intensity remains high, and the company is expanding production capacity amid robust global demand for nucleosides and specialty chemicals.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Pharmicell Co., Ltd